Clinical Trials on Castration-Resistant Prostate Carcinoma

Total 1397 results

Cardiff Oncology

Completed

Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States
Rahul Aggarwal
Merck Sharp & Dohme LLC; U.S. Army Medical Research and Development Command; Zenith...

Recruiting

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Metastatic Prostate Small Cell Carcinoma

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Hormone-Resistant Prostate Cancer

United States
University Hospital, Basel, Switzerland

Not yet recruiting

Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study (PROGNOSTICS)

Castration-resistant Prostate Cancer

Switzerland
Novartis Pharmaceuticals

Recruiting

A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With PSMA-positive Prostate Cancer With or Without Prior 177Lu-PSMA Radioligand Therapy.

Metastatic Castration-resistant Prostate Cancer (mCRPC)

France
Sidney Kimmel Comprehensive Cancer Center at Johns...
United States Department of Defense

Recruiting

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Castration Resistant Metastatic Prostate Cancer

United States
Noxopharm Limited

Terminated

A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

United States
University of Washington
National Cancer Institute (NCI)

Withdrawn

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Microsatellite Instability | Hormone-Resistant Prostate Cancer | Castration Levels of Testosterone

United States
OHSU Knight Cancer Institute
Janssen Scientific Affairs, LLC; Oregon Health and Science University

Active, not recruiting

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration-Sensitive Prostate Carcinoma

United States
Michael Graham PhD, MD
University of Iowa; Holden Comprehensive Cancer Center

Active, not recruiting

68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer

Prostate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Cancer Recurrent | Prostatic Cancer Metastatic

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Hormone-Resistant Prostate Cancer

United States
Karolinska Institutet
The Swedish Research Council; AstraZeneca; Janssen Pharmaceutica N.V., Belgium; Kom Op Tegen Kanker and other collaborators

Recruiting

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer (ProBio)

Metastatic Castration-resistant Prostate Cancer (mCRPC) | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Sweden, Belgium, Switzerland, Norway
Bayer

Terminated

A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels (CREDIT)

Bone Metastases | Metastatic Castration-resistant Prostate Cancer

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel (DEXTER)

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Rana McKay, MD
Bristol-Myers Squibb; Exelixis

Recruiting

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY)

Metastatic Cancer | Castration-resistant Prostate Cancer

United States
VA Office of Research and Development
Merck Sharp & Dohme LLC

Recruiting

A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation (CHOMP)

Metastatic Castration Resistant Prostate Cancer

United States
Novartis Pharmaceuticals

Completed

A Phase I Study of LFA102 in Japanese Patients

Castration-resistant Prostate Cancer, Advanced Breast Cancer

Japan
Roswell Park Cancer Institute
Active Biotech AB

Completed

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Novartis Pharmaceuticals

Active, not recruiting

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

China
Istituto Scientifico Romagnolo per lo Studio e...

Active, not recruiting

Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC) (LU-PSMA)

Metastatic Castration Resistant Prostate Cancer | 68Ga-PSMA PET/CT Positive

Italy
Jonsson Comprehensive Cancer Center
Novartis; Stand Up To Cancer; Prostate Cancer Foundation

Active, not recruiting

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Turku University Hospital

Recruiting

Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer (NeoADT-TULSA)

Prostate Cancer | Localized Prostate Carcinoma | Intermediate Risk Prostate Cancer | Castration-Naive Prostate Cancer

Finland
Michael Graham PhD, MD
University of Iowa; Holden Comprehensive Cancer Center

Completed

68Ga PSMA in Preprostatectomy Patients

Prostate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Neoplasm of Uncertain Behavior

United States
Pengyuan Liu

Recruiting

Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (CRPC)

China
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy (PROMOTE)

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Bayer

Completed

PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn (PRECISE)

Metastatic Castration-Resistant Prostate Cancer

Sweden
zr Pharma & GmbH

Completed

Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) (RAMP)

Metastatic Castration Resistant Prostate Cancer

United States
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC; Astex Pharmaceuticals, Inc.; Institute of Cancer Research...

Recruiting

Combination Study of Guadecitabine/ASTX727 and Pembrolizumab (HyPeR)

Non Small Cell Lung Cancer | Castration-Resistant Prostatic Cancer

United Kingdom
National Cancer Institute (NCI)

Terminated

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
University of Wisconsin, Madison
Merck Sharp & Dohme LLC; Prostate Cancer Foundation; Madison Vaccines, Inc

Active, not recruiting

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Prostate Cancer | Metastatic Cancer | Castration-resistant Prostate Cancer

United States
pharmaand GmbH
Foundation Medicine

Active, not recruiting

A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)

Metastatic Castration Resistant Prostate Cancer

United States, Canada, Spain, France, Australia, Ireland, Belgium, Denmark, United Kingdom, Germany, Israel, Italy
zr Pharma & GmbH
Foundation Medicine

Completed

A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)

Metastatic Castration Resistant Prostate Cancer

United States, Spain, United Kingdom, France, Australia, Belgium, Denmark, Israel, Germany, Ireland, Canada, Italy
OHSU Knight Cancer Institute
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation

Terminated

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Metastatic Prostatic Adenocarcinoma | Hormone-Resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
SpectronRX
Janssen Research & Development, LLC; Invicro; Tomopath Inc.

Terminated

Safety and Targeting of Anti-hk2 Antibody in mCRPC

Metastatic Disease | Castration-Resistant Prostatic Cancer

United States
National University Hospital, Singapore
National University of Singapore

Active, not recruiting

Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients

Prostate Cancer | Metastatic Cancer | Castration-resistant Prostate Cancer | Hormone Sensitive Prostate Cancer

Singapore
National Cancer Institute (NCI)

Completed

Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer

Canada
Northwestern University
National Cancer Institute (NCI)

Recruiting

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration-Sensitive Prostate Carcinoma

United States
Amgen

Completed

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Carcinoma | Cancer | Prostate Cancer | Tumors | Castrate-Resistant Prostate Cancer

United States, Canada, Poland, Hungary, Finland, Mexico
Blue Earth Therapeutics Ltd
PSI CRO

Recruiting

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Urogenital Neoplasms | Prostatic Neoplasms | Prostatic Diseases | Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | mCRPC

United States, Netherlands
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) (A-DREAM)

Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Castration-Sensitive Prostate Carcinoma

United States
Stanford University
National Cancer Institute (NCI)

Terminated

NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Hormone-Resistant Prostate Cancer

United States
Ipsen

Terminated

Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer (TasQ003)

Prostatic Neoplasms, Castration-Resistant

China, Korea, Republic of, Taiwan
University of Athens

Withdrawn

Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients (AERA)

Prostatic Neoplasms, Castration-Resistant
M.D. Anderson Cancer Center
Janssen Pharmaceutica

Active, not recruiting

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Aggressive Variant Prostate Carcinoma | Metastatic Prostate Neuroendocrine Carcinoma | Metastatic Prostate Small Cell Carcinoma

United States
Hansoh BioMedical R&D Company

Recruiting

ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC)

Metastasis Castration Resistant Prostate Cancer(mCRPC)

China
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide (UPWARD)

Metastatic Castration-resistant Prostate Cancer (mCRPC)

France, Germany, Spain, United States, Argentina, Australia, Belgium, Canada, Chile, Czechia, Finland, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Singapore, Sweden, Taiwan, United Kingdom
University of Michigan Rogel Cancer Center
Pfizer; Acrotech Biopharma Inc.

Recruiting

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Metastatic Breast Cancer | Metastatic Castration-resistant Prostate Cancer | Metastatic Ovarian Carcinoma

United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Metastatic Castration-resistant Prostate Cancer (mCRPC) | Clear Cell Renal Cell Carcinoma (ccRCC)

United States

Clinical Trials on Castration-Resistant Prostate Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations